Canada markets close in 2 hours 37 minutes

ImmunoGen, Inc. (IMU.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
4.0715-0.0620 (-1.50%)
As of 08:02AM CEST. Market open.

ImmunoGen, Inc.

830 Winter Street
Waltham, MA 02451-1477
United States
781 895 0600

Full Time Employees106

Key Executives

NameTitlePayExercisedYear Born
Mr. Mark Joseph EnyedyPres, CEO & Director1.24MN/A1964
Ms. Susan Altschuller Ph.D.Sr. VP & CFO537.53kN/A1983
Dr. Anna Berkenblit M.D., MM.ScSr. VP & Chief Medical Officer647.28kN/A1970
Ms. Stacy A. CoenSr. VP & Chief Bus. Officer547.66kN/A1971
Ms. Kristen Harrington-SmithSr. VP & Chief Commercial Officer562.52kN/A1973
Ms. Renee LentiniVP of Fin. & Principal Accounting OfficerN/AN/A1978
Ms. Courtney O'KonekSr. Director of Corp. Communications & Investor RelationsN/AN/AN/A
Mr. Joseph J. KennyVP, Acting Gen. Counsel, Intellectual Property & Sec.N/AN/AN/A
Ms. Audrey BerganSr. VP & Chief HR OfficerN/AN/AN/A
Dr. Theresa G. WingroveSr. VP of Regulatory Affairs & QualityN/AN/A1958
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

Corporate Governance

ImmunoGen, Inc.’s ISS Governance QualityScore as of June 1, 2022 is 4. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 5; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.